VISION
Inspiring transformational change in the
field of oncology diagnostics
MISSION
To develop and deliver accurate, rapid, minimally
invasive oncology diagnostic products utilising our
patented MCM5 antibodies
Arquer Diagnostics is focused on the development and commercialisation of highly accurate minichromosome maintenance (MCM) protein based non-invasive tests for cancer diagnosis and monitoring.
Arquer aim to meet demand expressed by patients, clinicians and payers for cost-effective healthcare technologies that not only enhance patient care but help to reduce overall healthcare costs by improving patient outcomes.
Latest News
@ArquerDx
#SIU2017 comes to a close today. It's been a pleasure to be here, and thank you to everyone involved in the launch… https://t.co/FahMbx5mS9
@ArquerDx
RT @alphalabs: Missed @ArquerDx SIU@U Studio Session yesterday? Still available on-demand on SIU@U #bladder #cancer #Diagnostics
Visit it…
@ArquerDx
Here’s a #selfie of our CEO, Nadia Whittley, at a studio session on #ADXBLADDER - it’s almost time to launch!… https://t.co/rOy8omh5iF